The U.K. National Institute for Health and Clinical Excellence rejected the use of Sanofi's Zaltrap to treat bowel cancer because of its expense. The drug is not cost-effective despite the discount offered by Sanofi, NICE said. The drug has also taken the spotlight in the U.S. due to its high price.

Full Story:

Related Summaries